Search the archive: |
| | |
In response to the growing problem of counterfeit drug production and distribution, the consultancy firm Capgemini has created a Pharmaceutical RFID Centre of Excellence to help pharmaceutical firms pilot drug pedigree technologies and help eliminate counterfeit drugs.
According to Capgemini, counterfeit drugs in the global supply chain cost the pharmaceutical industry US$50-US$100 million a year per company in lost revenue and brand reputation damage, and present potentially serious risks to patients in need of the actual prescribed medication.
Technology partners
Capgemini has launched the new initiative in Cambridge, Massachusetts, with software vendor SupplyScape to deliver an open, secure development environment for the testing of anti-counterfeiting RFID pilot schemes. Capgemini's technology partners also participated in the development of the centre, including Sun Microsystems and ADT Security Systems (a division of Tyco Fire & Security).
FDA obligations
"Counterfeit drugs don't just create a patient safety issue, they are also a serious business problem," said Paul Nannetti, global life sciences leader for Capgemini. "By maximising brand security within the proposed FDA timeline, the pharmaceutical industry can meet its obligations and achieve significant returns on investment as well as improvements in efficiency and accuracy."
"We're confident that our relationship with SupplyScape will enable us to implement standards and procedures to help combat drug counterfeiting business problems industry-wide," commented Derek Crates, global leader for life science technology solutions at Capgemini.
Source: Capgemini Group
|
